PhaseBio Pharmaceuticals
Manufacturing · Pennsylvania, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
1 Great Valley Pkwy Ste 30, Malvern, Pen...Phone Number
(610) 981-6500Website
www.phasebio.comRevenue
<$5 MillionStock Symbol
PHASIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat cardiopulmonary diseases. The company's lead development candidate is PB2452, a novel reversal agent for the antiplatelet therapy ticagrelor. PhaseBio is also leveraging its proprietary elastin-like polypeptide ("ELP") technology platform to develop therapies with the potential for less-frequent dosing and improved pharmacokinetics. PhaseBio's second product candidate PB1046, which is based on ELP, is a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension.Explore more
PhaseBio Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is PhaseBio Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if PhaseBio Pharmaceuticals had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at PhaseBio Pharmaceuticals
Earning: See what the market has to say on PhaseBio Pharmaceuticals recently announced quarterly report
Check if PhaseBio Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Check out if PhaseBio Pharmaceuticals is spiking on competitors!
Funding: Get notified immidiatlly once PhaseBio Pharmaceuticals has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
PhaseBio Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when PhaseBio Pharmaceuticals launches new products
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to PhaseBio Pharmaceuticals
Compare insights from companies similar to PhaseBio Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$19.9M
51-200
Private
$300M
2016
RC
Ryan CarteExecutive Vice President & General Counsel & Corporate Secretary
Company Profile Activity
Activity Insights
PhaseBio Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
PhaseBio Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about PhaseBio Pharmaceuticals.
PhaseBio Pharmaceuticals financials insights
Gather financial insights about PhaseBio Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2002
Series A
$25K
2012
Series B
$54.6M
2015
Series C
$40M
2017
Debt
$22.8M
Debt
$7.5M
2018
Multiple Rounds
$79.8M
2019
Debt
$15M
Stock Offering
$49.5M
2020
Other Financing Round
$120M
PhaseBio Pharmaceuticals Tech Stack
A closer look at the technologies used by PhaseBio Pharmaceuticals
Most Recent Scoops
Left Company
Executive Move
Left Company
Executive Move
Left Company
Executive Move
Left Company
Management Move
PhaseBio Pharmaceuticals News & Media
PhaseBio Files for Bankruptcy Following Blackstone-Backed Partner's Lawsuit - WSJ
PhaseBio Pharmaceuticals Inc., a publicly traded heart-disease drug developer, filed for chapter 11 bankruptcy protection weeks after being sued for breach of contract by a Blackstone Inc. portfolio company.PHASEBIO PHARMACEUTICALS INC : Bankruptcy or Receivership, Other Events, Financial ...
Item 1.03 Bankruptcy or Receivership. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for relief under Chapter 11 of Title 11 of the United States Bankruptcy Code ... | October 24, 2022PhaseBio Plans for Near-Term Sale Using Structured Process Through Chapter 11 of U.S. Bankruptcy Code
MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Plans for Near-Term Sale Using Structured Process Through Chapter 11 of U.S. Bankruptcy CodePhaseBio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Business Highlights
MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Business Highlights
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding PhaseBio Pharmaceuticals
Sign Up For FreeTo access detailed company insights
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat cardiopulmonary diseases. The company's lead development candidate is PB2452, a novel reversal agent for the antiplatelet therapy ticagrelor. PhaseBio is also leveraging its proprietary elastin-li... Read More
